表紙
市場調查報告書
商品編碼
366042

IV-to-SC轉用藥 (從靜脈給藥到皮下注射治療的轉用藥)的市場

Intravenous-to-Subcutaneous Drug Repositioning

出版日期: | 出版商: Greystone Research Associates | 英文 | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

從靜脈給藥的相對的複雜性和成本,患者管理的必要性,被向靜脈給藥劑的市售後的皮下注射治療劑轉用關心寄(移),因為這個轉用,現在,幾個技術性方法被採用。

本報告提供IV-to-SC轉用藥 (從靜脈給藥到皮下注射治療的轉用藥)的市場調查,轉用技術,轉用藥的產品分析,各疾病領域趨勢,市場影響因素分析,企業及企業間的配合措施,新技術趨勢,以及主要企業的簡介等彙整。

摘要整理

市場機會

  • 市場部門動態
  • 從靜脈給藥到皮下注射治療:市場機會
  • IV-to-SC轉用藥的市場促進因素
  • 管理護理&醫療保健的經濟學
  • 患者感情
  • 投藥設備的創新
  • 患者/生命週期策略
  • 競爭環境
  • 風險因素

IV-to-SC轉用技術

  • 製劑
  • 注射部位的變更
  • 投藥設備的創新
  • 發展因素
  • 人因工程/人體工學
  • 冷凍乾燥藥/重組

IV-to-SC轉用藥:產品分析

  • 抗生素
  • 抗體
  • 抗凝固藥
  • 制吐藥
  • 血液因子
  • 利尿劑
  • 荷爾蒙藥
  • 血漿來源免疫抑制劑
  • 重組免疫療法藥
  • 血管擴張藥

IV-to-SC轉用藥:疾病領域分析

  • 心臟
  • 水腫
  • 高血壓
  • 血小板抑制
  • 血液
  • 多發性硬化症
  • 癌症
  • 生殖健康

市場因素

  • 法律規章上的課題
  • 合作、聯盟
  • 新的技術

企業簡介

目錄
Product Code: JSD393K

Re-engineering IV Drugs

As the pace of competition increases within the pharmaceutical and biotech industries, the concept of life cycle management is becoming a key component of drug product management. Much of the recent emphasis in this area has centered on efforts to extend patent rights protection. While reformulation has been and is an important approach, efforts to prolong IP benefits have only recently involved IV-to-SC drug re-engineering. This migration path is now becoming a significant pathway in the life cycle of many parenteral drugs. A number of technology approaches are currently being employed to accomplish this migration. By pursuing IV-to-SC strategies, drug owners are finding they can achieve a number of competitive advantages.

Intravenous-to-Subcutaneous Drug Markets - What You Will Learn:

  • What intravenous drugs have been strategically re-engineered for subcutaneous administration, what are the technologies being used, and what is their current market status?
  • What are the therapeutic markets that are viewed as having the greatest potential for IV-to-SC migration?
  • What are the major factors driving intravenous-to-subcutaneous drug re-engineering?
  • How are intravenous-to-subcutaneous drugs currently aligned with drug classes and therapeutic markets?
  • What intravenous drugs are currently being developed for eventual release as subcutaneously administered drugs, and what is their current status?
  • What is the market impact of IV-to-SC drug migration? What will it be in 2024?
  • Who are the significant players in this segment? What are their strategies? Who are their alliance partners?

Table of Contents

Executive Summary

  • Intravenous-to-Subcutaneous Market Dynamics

IV-to-SC Repositioning - The Market Opportunity

  • The Addressable Market
  • Market Drivers
  • Patient-centric Therapeutics
  • Device Evolution and Enablement
  • Patent Life and IP Strategies
  • Managed Care and Healthcare Economics
  • Product Development Factors
  • Lyophilized Drugs/Reconstitution
  • Human Engineering/Ergonomics
  • Competitive Landscape
  • Risk Factors
  • Intravenous-to-Subcutaneous Technology
  • Drug Formulation
  • Injection Site Modification
  • Device Innovation

IV-to-SC Repositioning - Product Segment Analysis

  • Device Analysis
  • Wearable SC Infusors
  • Wearable SC Injectors
  • Drug Product Analysis
  • Antibiotics
  • Blood Factors
  • CSL Behring (Enable Injections)
  • Diuretics
  • Antiemetics
  • Hematopoietics
  • Immune Factors
  • Immunoglobulin G (Hyqvia/Baxalta)
  • Immunotherapeutics
  • Vasodilators
  • Prostacyclin (SteadyMed Therapeutics)
  • Remodulin (United Therapeutics)

IV-to-SC - Therapeutic Sector Analysis

  • Cardiology
  • Edema
  • Pulmonary Arterial Hypertension
  • Hematology
  • Blood Factors
  • Oncology
  • Market Factors
  • Regulatory Issues
  • Collaborations and Alliances
  • Emerging Technologies

Company Profiles